Sotera Health Company (NASDAQ:SHC) Receives $16.00 Average PT from Analysts

Sotera Health Company (NASDAQ:SHC - Get Free Report) has received an average recommendation of "Moderate Buy" from the five brokerages that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $16.00.

Several equities analysts have weighed in on the company. Piper Sandler cut their price target on Sotera Health from $15.00 to $13.00 and set a "neutral" rating for the company in a report on Wednesday, April 23rd. Wall Street Zen upgraded Sotera Health from a "hold" rating to a "buy" rating in a report on Saturday, June 28th. The Goldman Sachs Group upgraded Sotera Health from a "neutral" rating to a "buy" rating and raised their price target for the company from $14.00 to $17.00 in a report on Monday, May 5th. Finally, Barclays cut their price target on Sotera Health from $15.00 to $13.00 and set an "overweight" rating for the company in a report on Tuesday, June 24th.

Sotera Health Price Performance

SHC traded up $0.11 on Wednesday, hitting $11.75. 425,726 shares of the company's stock traded hands, compared to its average volume of 1,231,578. The company's 50 day simple moving average is $12.07 and its 200-day simple moving average is $12.33. The firm has a market cap of $3.33 billion, a price-to-earnings ratio of 146.83 and a beta of 1.81. Sotera Health has a one year low of $9.53 and a one year high of $17.08. The company has a current ratio of 2.46, a quick ratio of 2.19 and a debt-to-equity ratio of 5.55.

Sotera Health (NASDAQ:SHC - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.02. The company had revenue of $254.52 million for the quarter, compared to the consensus estimate of $245.56 million. Sotera Health had a return on equity of 41.08% and a net margin of 2.24%. The firm's quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter last year, the company earned $0.13 EPS. As a group, research analysts anticipate that Sotera Health will post 0.61 EPS for the current year.

Hedge Funds Weigh In On Sotera Health

Several large investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of Sotera Health by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 14,923,546 shares of the company's stock valued at $204,154,000 after purchasing an additional 173,341 shares during the last quarter. Sculptor Capital LP increased its position in shares of Sotera Health by 80.8% during the 1st quarter. Sculptor Capital LP now owns 9,037,511 shares of the company's stock valued at $105,377,000 after purchasing an additional 4,037,511 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its position in shares of Sotera Health by 5.9% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 8,045,502 shares of the company's stock valued at $93,811,000 after purchasing an additional 450,761 shares during the last quarter. TPG GP A LLC bought a new position in shares of Sotera Health during the 1st quarter valued at approximately $79,126,000. Finally, Two Seas Capital LP increased its position in shares of Sotera Health by 14.7% during the 1st quarter. Two Seas Capital LP now owns 3,321,136 shares of the company's stock valued at $38,724,000 after purchasing an additional 425,000 shares during the last quarter. Institutional investors own 91.03% of the company's stock.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.